McKesson raised its profit forecast, aiming to focus on high-margin businesses like cancer medicines. Adjusted earnings now expected to range between $38.05 and $38.55 per share for fiscal 2026, up from $37.10 to $37.90. Long-term adjusted earnings growth target raised to 13% to 16%. Shares rose 6% post-announcement. CEO Brian Tyler optimistic about company’s impact in healthcare ecosystem. McKesson reorganized its business last week, including a new oncology and multispecialty unit. Segment expected to grow 13% to 16% annually, fastest among divisions. Prescription technology solutions targeting 10% to 13% growth, North American pharmaceutical segment aiming for 5% to 8% growth. Analysts view update positively ahead of investor day. McKesson expanding in oncology through acquisitions and partnerships, including $2.49 billion stake in Core Ventures. Operating environment focus during investor day, amid investor concerns about drug pricing. McKesson to update investors on planned separation of medical-surgical solutions unit.

Read more at Yahoo Finance: McKesson lifts annual profit forecast on plans to focus on high-margin businesses